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Abstract
The shift towards primary human papillomavirus (HPV)-based screening has necessi-
tated the search for a secondary triage test that provides sufficient sensitivity to
detect high-grade cervical intraepithelial neoplasia (CIN) and cancer, but also brings
an improved specificity to avoid unnecessary clinical work and colposcopy referrals. We
evaluated the performance of the previously described DNA-methylation test (S5) in
detecting CIN3 and cancers from diverse geographic settings in high-, medium- and low-
income countries, using the cut-off of 0.80 and exploratory cut-offs of 2.62 and 3.70.
Assays were performed using exfoliated cervical specimens (n = 808) and formalin-fixed
biopsies (n = 166) from women diagnosed with cytology-negative results (n = 220),
CIN3 (n = 204) and cancer stages I (n = 245), II (n = 249), III (n = 28) and IV (n = 22).
Methylation increased proportionally with disease severity (Cuzick test for trend,
P < .0001). S5 accurately separated women with negative-histology from CIN3 or cancer
(P < .0001). At the 0.80 cut-off, 543/544 cancers were correctly identified as S5 positive
(99.81%). At cut-off 3.70, S5 showed a sensitivity of 95.77% with improved specificity.
The S5 odds ratios of women negative for cervical disease vs CIN3+ were significantly
higher than for HPV16/18 genotyping at all cut-offs (all P < .0001). At S5 cut-off 0.80,
96.15% of consistently high-risk human papillomavirus (hrHPV)-negative cancers (tested
with multiple hrHPV-genotyping assay) were positive by S5. These cancers may have
been missed in current primary hrHPV-screening programmes. The S5 test can accu-
rately detect CIN3 and malignancy irrespective of geographic context and setting. The
test can be used as a screening and triage tool. Adjustment of the S5 cut-off can be
performed considering the relative importance given to sensitivity vs specificity.
Abbreviations: CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; hrHPV, high-risk human papillomavirus; IQR, interquartile range; LMICs, low- and
middle-income countries; OR, odds ratio, PCR, Polymerase Chain reaction, FIGO, Fédération Internationale de Gynécologie et d'Obstétrique; LMICS, Low and Medium Income Countries.
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What's new?
In recent years, cervical cancer screening has shifted towards high-risk human papilloma virus
(HPV) testing with triage of HPV-positive women through cytology. Here, the authors confirm
that the S5 DNA-methylation test can accurately detect and predict high-grade cervical intra-
epithelial neoplasia and cervical cancer, irrespective of the setting and geographic context. The
S5 test cut-off can be adjusted to reflect the relative importance given to sensitivity versus
specificity, and the S5 test-score is directly proportional to disease severity. An objective bio-
marker test like S5 coupled with minimally-invasive self-sampling strategies could potentially
improve the utilisation of healthcare resources and save lives globally.
1 | INTRODUCTION
The implementation of cervical cancer prevention programmes by sys-
tematic cytology screening1 has contributed to a reduction in cervical
cancer-associated deaths in high-income countries.2 Yet, cervical can-
cer is currently the fourth most common cancer in women and con-
tinues to increase worldwide, with 604 000 cases in 2020, accounting
for 7.5% of all female cancer deaths.3 To allow a further reduction in
the incidence of cervical cancer, screening has shifted towards high-
risk human papillomavirus (hrHPV) testing with triage of HPV-positive
women. Cervical cancer incidence, ranges from 5 to 50 per 100 000
women depending on setting and while hrHPV testing is highly sensi-
tive for the detection of disease, specificity is less optimal given the
benign trajectory of most infections. Triage generally relies on cytol-
ogy as the preferred secondary test in HPV-positive women.4 How-
ever, being subjective, cytology has limitations and objective
secondary triage tests are urgently needed to identify the minority of
hrHPV-positive women with high-grade disease.4 Furthermore, triage
tests that rely on molecular rather than morphological signatures (such
as cytology) remove the requirement for specialised expertise.
Methylation biomarkers can offer an accurate alternative to
detect clinically significant infection and associated disease and can
identify women who have the highest risk of progressing into invasive
cervical cancer.5,6 Aberrant DNA methylation has been reported to
increase with cervical cancer disease progression,7 allowing this epige-
netic event to be used as a temporal biomarker, with a potential to
accurately predict whether hr-HPV infection will lead to cervical intra-
epithelial neoplasia grade 2 or above (CIN2+) or disappear.5,8
Several methylation biomarkers tests including our S5 DNA-
methylation classifier, which tests for methylation on the host tumour
suppressor gene EPB41L3 and viral late genes (L1 and L2) of HPV16,
HPV18, HPV31 and HPV33, can accurately separate women with
CIN2/3 and cancer from those with CIN1 or normal cytology.9 The
S5-classifier has demonstrated improved triage performance compared
to hrHPV genotyping, cytology or the combination thereof and has
been validated in a HPV-positive cohort of women as part of the Cana-
dian FOCAL clinical trial, in the FRIDA screening trial in Mexico and the
Colombian ASC-US-COL trial.10-12 Additionally, the S5-classifier dem-
onstrated a potential prognostic utility, in its ability to identify women
with progressive CIN2.8 Together, these data support the prospect of
using the S5-classifier as a molecular tool to identify clinically significant
cervical abnormalities and predicting their clinical course.
Validation of the S5-classifier in a large number of CIN3+ samples
from both high-income and low- and middle-income countries (LMICs) is
required to demonstrate that the methylation test can consistently
detect cervical cancers worldwide. Extensive validation of the S5 classi-
fier will support implementation of the test in global screening and
disease-management systems, especially with the rise in acceptance of
screening based on self-sampling.13,14 The main objective of the present
study is to analyse the performance and consistency of S5 in detecting
high-grade lesions and cervical cancers from diverse settings that reflect
Asia, Europe, Africa and the Americas. The present study aims to comple-
ment previous works on the S5 DNA-methylation classifier.6,9,11,12,15
2 | MATERIALS AND METHODS
2.1 | Study population
Cervical swabs and biopsies were collected from a total of
973 patients aged 21 to 64 as described in the referenced
papers.16-22 All samples included in the study were analysed by
cytology or histology and had results of negative, CIN3 or invasive
cervical cancer. We excluded CIN1 and CIN2 from our study
because the CIN1 is a low-grade lesion and CIN2 is considered
increasingly, a heterogenous lesion that does not serve as a robust
histological indicator of high-grade disease. Our study focussed
mainly on cervical cancer stages I and II in order to have a sharper
view of the epigenetic contrast between CIN3 vs early cancer and
to complement previously published data on S5 performance.
Details regarding patient characteristics are described in Table 1.
The cellular material for cervical liquid-based cytology samples
was collected in PreservCyt medium (Hologic Corporation,
Marlborough, MA) for storage until DNA extraction. A subset of
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specimens from Bhutan (n = 10), Ethiopia (n = 49), India (n = 10),
Spain (n = 20), United Kingdom (n = 51), Colombia (n = 20) and
United States (n = 50) were selected for negative cytology results.
CIN3 samples originated from Spain (n = 50), United Kingdom
(n = 54), Colombia (n = 50) and United States (n = 50). Cancer sam-
ples originated from Ethiopia (n = 70), South Africa (n = 49), Bhutan
(n = 50), India (n = 50), Philippines (n = 50), Georgia (n = 42), Spain
(n = 50), United Kingdom (n = 51), Colombia (n = 46) and
United States (n = 86). All CIN3 and cancer samples were collected
from patients showing abnormal cytology and histology results
through colposcopy referral and diagnosed according to specific coun-
try recommendations. Biopsy samples were collected and stored at
70C (IARC and Scottish HPV Archive and Addis Ababa University);
formalin-fixed paraffin-embedded (FFPE) samples were stored at
room temperature (Bhutan-IARC and University of New Mexico) until
DNA was extracted.
TABLE 1 Baseline characteristics of the 973 women from the study cohort
Cervical cancer – FIGOa stage
Characteristics
HPV()/Cyt()a HPV(+)/Cyt()a CIN3a Stage Ia Stage IIa Stage IIIa Stage IVa
n = 110 (%) n = 110 (%) n = 204 (%) n = 245 (%) n = 249 (%) n = 28 (%) n = 22 (%)
Histotype of cervical cancer
Squamous cell carcinoma 230 (93.9) 236 (94.8) 26 (92.8) 19 (86.5)
Adenocarcinoma 14 (5.7) 10 (4.0) 2 (7.2) 2 (9.0)
Adenosquamous cell carcinoma — 1 (0.4) — —
Neuroendocrine carcinoma 1 (0.4) 2 (0.8) — 1 (4.5)
hr-HPV statusa
Consistently negative 110 (100) — 10 (4.90) 14 (5.7) 10 (4.0) 2 (7.1) —
HPV16+ — 35 (31.8) 120 (58.8) 160 (65.3) 179 (72.1) 20 (71.4) 19 (86.4)
HPV18+ — 14 (12.7) 7 (3.4) 19 (7.7) 15 (6.0) 1( 3.5) —
HPV31+ — 6 (5.5) 30 (14.7) 8 (3.2) 9 (3.6) 2 (7.1) 1 (4.5)
HPV33+ — 6 (5.5) 7 (3.4) 9 (3.6) 8 (3.2) — —
Other hr-HPV+ — 49 (44.5) 30 (14.7) 35 (14.3) 28 (10.8) 3 (10.7) 2 (9.1)
Sample type
Cervical scrape 110 (100) 110 (100) 204 (100) 142 (58.0) 192 (77.0) 28 (100) 22 (100)
FFPE tissuea — — — 103 (42.0) 57 (22.9) — —
Age (years)
<25 20 (18.18) 12 (10.9) 14 (6.9) 5 (2.0) 2 (0.8) — —
25-29 27 (24.5) 25 (22.7) 59 (28.9) 27 (11.0) 10 (4.0) — 1 (4.5)
30-39 28 (25.4) 26 (23.6) 81 (39.7) 83 (33.8) 43 (17.3) 4 (14.2) 3 (13.6)
40-49 21 (19.0) 23 (20.9) 30 (14.7) 56 (22.8) 84 (33.8) 8 (28.5) 6 (27.4)
50-59 8 (7.2) 12 (10.9) 14 (6.9) 46 (18.7) 63 (25.4) 9 (32.1) 11 (50.0)
>60 6 (5.5) 12 (10.9) 6 (2.9) 28 (11.4) 47 (18.5) 7 (25.0) 1 (4.5)
Country of origin
Bhutan — 10 (9.0) — 28 (11.4) 22 (8.8) — —
Colombia 16 (14.5) 4 (3.6) 50 (24.2) 21 (8.5) 25 (10.0) — —
Ethiopia 39 (35.5) 10 (9.0) — 2 (0.8) 18 (7.2) 28 (100) 22 (100)
Georgia — — — 40 (16.3) 2 (0.8) — —
India — 10 (9.0) — 12 (4.9) 38 (15.3) — —
Philippines — — — 15 (6.1) 35 (14.1) — —
South Africa — — — 2 (0.8) 47 (18.9) — —
Spain 16 (14.5) 4 (3.6) 50 (24.2) 28 (11.4) 22 (8.8) — —
United Kingdom 25 (22.7) 36 (32.7) 54 (27.1) 48 (19.5) 3 (1.2) — —
United States (New Mexico) 14 (12.7) 36 (32.7) 50 (24.2) 50 (20.4) 36 (14.5) — —
Note: All women were diagnosed as histology negative (healthy women), cervical intraepithelial neoplasia Grade 3 (CIN3) and cervical cancer stages I-IV.
Abbreviations: FFPE, formalin-fixed paraffin-embedded; FIGO, Fédération Internationale de Gynécologie et d'Obstétrique; HPV, human papillomavirus; hr-
HPV, high-risk human papillomavirus.
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2.2 | S5-methylation assays
DNA was extracted using (a) QIAsymphony DSP DNA Mini Kit
(Qiagen, Hilden, Germany) for all samples in the IARC biobank (both
PreservCyt and FFPE specimens); (b) Abbott M2000 system (Abbott
Laboratories, Maidenhead, UK) for all samples in the Scottish HPV
Archive biobank; (c) DNA from Ethiopian samples and FFPE tissue
from University of New Mexico was manually extracted using DNeasy
Blood & Tissue Kit (Qiagen). After extraction, DNA was quantified
with the Qubit Flex Fluorometer (Thermofisher Scientific, London,
UK). One hundred nanograms of DNA was used in the bisulphite con-
version reaction where un-methylated cytosines were converted to
uracils with the EZ DNA methylation kit (Zymo Research, Irvine, CA).
The converted DNA was amplified and pyrosequenced on a PyroMark
Q96ID (Qiagen) for DNA methylation on CpG islands from EPB41L3
and viral late genes (L1 and L2) of HPV16, HPV18, HPV31 and
HPV33 as previously described.9 Percentage methylation was taken
as the mean for CpG sites involved in each case.
2.3 | HPV genotyping
The clinical samples used in the study have been initially genotyped as
part of previously approved research studies. The following technologies
were used: GP5+/6+ PCR assay (n = 641),17,18,20,21 Abbott RealTime
assay (n = 126), Roche LINEAR ARRAY HPV Genotyping assay (n = 88)
and BD Onclarity assay (n = 52). Genotyping with Papilloplex High-Risk
HPV test (GeneFirst, Oxford, UK) was additionally used to validate previ-
ous HPV genotyping in all samples investigated. This is a multiplexed
polimerase chain reaction (PCR)-based system that simultaneously
detects 13 hr-HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 68 and the low-risk type 66).23 Genotyping with the Papilloplex
High-Risk HPV test was run in house on the QuantStudio 5 Real-Time
PCR System (Thermofisher Scientific) and targeted the L1 region of all
the genotypes described. Papilloplex High-Risk HPV internal negative
and positive controls were used as baselines and analysis was performed
on the GeneFirst software.
We investigated the following HPV categories: (a) HPV16 posi-
tive, (b) HPV18 positive, (c) HPV31 positive, (d) HPV33 positive and
(e) other hr-HPV positive (non-HPV16/18/31/33). We followed a
hierarchical attribution of HPV genotypes, namely in cases with multi-
ple hrHPV-infections the more prevalent genotype in cancer was
attributed dominant status (eg, a sample positive for both HPV16 and
HPV18 was placed in category 1).
2.4 | Statistical analysis
We validated the performance sensitivity of the S5 classifier on CIN3
and cervical cancer samples from a global population of samples. We
used the mean of methylation scores for selected CpG sites: three for
EPB41L3 (438, 427, 425), two for HPV16L1 (6367, 6389), six for
HPV18L2 (4256, 4261, 4265, 4269, 4275, 4282), two for HPV31L1
(6352, 6367) and three for HPV33L2 (5557, 5560, 5566) as previ-
ously described.9,15,24-26 Proportion of methylation on HPV16L2 was
calculated using the following three CpG sites: 4275, 4259 and 4238
as they were the most reproducible sites in this region. The
S5-methylation score was calculated by using the following weighed
average defined in 2016 by Lorincz et al9:
S5¼30:9 EPB41L3ð Þþ13:7 HPV16L1ð Þþ4:3 HPV16L2ð Þ
þ8:4 HPV18L2ð Þþ22:4 HPV31L1ð Þþ20:3 HPV33L2ð Þ:
The main groups being compared were HPV negative cytology negative:
HPV()/Cyt(), HPV-positive cytology negative: HPV(+)/Cyt(), CIN3
and cervical cancer including stages I (CSI), II (CSII), III (CSIII) and IV (CSIV)
as per Fédération Internationale de Gynécologie et d'Obstétrique (FIGO)
stage classification. We hypothesised that uniformity in proportions
and/or levels of methylation status among the different lesion categories
may imply prognostic value as a clinical marker.
We compared differences in methylation levels between groups
using Kruskal-Wallis and Dunn's multiple comparison tests and the
Cuzick test for trend to assess any methylation trend with disease
progression. We evaluated the S5 diagnostic potential using the pre-
defined cut-off of 0.80. In addition, we explored cut-off points more
suited for LMIC, using a previously defined alternative cut-off and
Youden-J index.12 McNemar's test with continuity correction was
used for differences in sensitivity and specificity.
We also used unconditional logistic regression to study the relation-
ship between methylation in the invasive cervical cancer group and the
covariates – stage of cancer, type, age, demographics and HPV status.
Additionally, we calculated the odds ratios (ORs) for the associations
between HPV16/18 positivity, S5 classifier positivity at different cut-offs
and CIN3 or cervical cancer (CSI-IV, FIGO stage unknown included) diag-
nosis. All P values were two-sided with α ≤ .05 considered significant.
Analysis was performed with GraphPad Prism v8.0 as well as R v 3.4.1
for Cuzick tests, ORs and for unconditional logistic regression analyses.
3 | RESULTS
3.1 | Characteristics and selection criteria
We present a cross-sectional retrospective study including 973 women
from 10 countries to evaluate the S5 methylation classifier performance to
detect CIN3 and cervical cancer. The present study aims to complement
previous work on the S5 DNA-methylation classifier.6,9,11,12,15 We selected
220 women cytology negative or HPV(/+)/Cyt(), 204 women diag-
nosed with CIN3 and 544 with invasive cervical cancer as described in
Figure 1. Baseline characteristics of the women are presented in Table 1.
The invasive cervical cancer group is further divided into squamous cell car-
cinomas (n = 510), adenocarcinomas (n = 29), adenosquamous cell carci-
nomas (n = 1) and neuroendocrine small cell carcinoma (n = 4). The
median age for women with negative cytology was 38 years [interquartile
range (IQR), 30-47], for CIN3 was 31 years (IQR, 28-39) and for women
with invasive cervical cancer was 45 years (IQR, 38-55).
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3.2 | hrHPV detection
The Papilloplex High-Risk HPV genotyping data were in 98.23% [95%
confidence interval (CI) = 96.38%-99.99%) agreement with previous
genotyping methodologies used (Figure 1). The grouped prevalence of
13 types of hrHPV plus HPV66 (now regarded as a low-risk HPV) was
95.09% (95% CI = 92.13%-97.89%) in the CIN3 group and 95.21%
(95% CI = 92.45%-98.12%) in the cancer group. Each type of HPV in
women infected by multiple HPV types was counted individually as
described in Table 1 and Figure S1. In the cancer group, 374 women
were consistently positive for HPV16 (68.91%), 37 women for HPV18
(6.91%), 21 women for HPV31 (3.90%), 16 women for HPV33 (3.01%)
and 68 women for other hr-HPV types (12.41%). A total of 25 (4.78%)
cervical cancers tested negative for any hr-HPV type covered by the
assays. HPV genotyping was in agreement with methylation data on
HPV16/18/31/33 infection in 95.38% (95% CI = 91.38%-98.33%) of
cases.
3.3 | Increasing trend in the S5 methylation scores
with disease severity
The S5methylation scores were clustered according to severity of cervical
abnormality. An outline of the methylation scores per country is provided
in Figure S2. Median methylation score was 0.66 (95% CI = 0.60-0.78) in
HPV negative and cytology negative women [HPV()/Cyt()], 0.91
(95%CI= 0.86-0.94) in HPV positive and cytology negative women [HPV
(+)/Cyt()], 5.64 (95% CI = 3.99-6.88) in CIN3, 17.58 (95% CI = 15.99-
20.33) in cervical cancer stage I (CSI), 23.71 (95%CI= 21.67-25.24) in cer-
vical cancer stage II (CSII), 24.44 (95%CI= 22.10-32.14) in cervical cancer
stage III (CSIII) and 24.95 (95% CI = 22.34-32.85) in cervical cancer stage
IV (CSIV). The distribution of the S5 scores based on the disease diagnosis
and hr-HPV status is shown in Figure 2A. Kruskal-Wallis andDunn's multi-
ple comparisons tests show significant separation in the following paired
comparisons: HPV()/Cyt() vs CIN3 (P < .0001), HPV()/Cyt() vs CSI-
IV (all P < .0001), HPV(+)/Cyt() vs CIN3 (P < .0001), HPV(+)/Cyt() vs
F IGURE 1 Study design flow chart
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CSI-IV (all P < .0001), CIN3 vs CSI-IV (all P < .0001). No other significant
differences were identified. The S5-classifier scores increased significantly
with the severity of lesions (Cuzick test for trend: z= 9.23, P < .0001).
3.4 | S5-classifier sensitivity in cervical cancers
at the 0.80 predefined cut-off
The S5-classifier methylation score was successfully measured in all
544 women diagnosed with cervical cancer which were included in the
study. A total of 543 out of 544 cancer patients tested positive for S5 at
0.80, yielding a sensitivity of 99.81% (95% CI = 98.34-99.96). Table 2
shows the S5 sensitivity stratified per histology, FIGO stage, hrHPV status,
hrHPV type, sample type, age and country of origin. At the 0.80 cut-off,
cervical cancers which were consistently hrHPV negative when tested
with multiple hrHPV genotyping assays were 96.15% (95% CI = 94.38-
98.25) identified by the S5 classifier. The performance of the S5 classifier
was uniform among all groups considered. There were no significant dif-
ferences in S5 sensitivity among histology, FIGO stage, hrHPV type, sam-
ple type, age and country of origin (Fishers' test, all P > .05).
3.5 | S5 classifier cut-off adjusted per country
to optimise triage capacity
Cervical cancer incidence is directly linked to the availability of
screening in a particular country. Hence the importance to introduce
different modalities for the implementation of a molecular triage
reflecting the country clinical setting. We investigated the false posi-
tive rates in women with HPV()/Cyt(), HPV(+)/Cyt(), CIN3 and
CSI-IV at the UK-predefined cut-off of 0.80, the Youden-J index cut-
off based on the S5 methylation scores of cervical cancers: 2.62 and
the previously explored LMIC cut-off of 3.70.12 For all groups

















































































































































































F IGURE 2 S5 performance in the study group: (A) Distribution of the S5 scores based on the histopathological diagnostic of the patient. Data
were plotted as log 10 of the S5 score according to lesion grade: HPV()/Cyt(), HPV(+)/Cyt(), CIN3 and all stages of cervical cancer (CSI-IV).
The S5 classifier was significantly different between the following group comparisons: HPV()/Cyt() vs CIN3 (P < .0001), HPV()/Cyt() vs CSI-
IV (all, P < .0001), HPV(+)/Cyt() vs CIN3 (P < .0001), HPV(+)/Cyt() vs CSI-IV (all, P < .0001) and CIN3 vs CSI-IV (all, P < .0001). Other
comparisons were not significant [HPV()/Cyt() vs HPV(+)/Cyt(), among CSI-IV]. The proposed cut-offs for analysis are: 0.80 (red), 2.62 (blue)
and 3.70 (green). The top of box represents the upper quartile (p75), bottom the lower quartile (p25) and the line the median (p50). The upper
whisker extends to the largest point of the inter-quartile range from the upper quartile. The lower whisker extends to the smallest point of the
inter-quartile range from the lower quartile. The Cuzick test for trend was highly significant (P < .0001). (B) Cumulative S5 positivity per lesion
grade at the three cut-offs: 0.80 (red), 2.62 (blue) and 3.70 (green). Median values are shown by each bar and error bars show 95% CI of the
median. CI, confidence interval; CIN, cervical intraepithelial neoplasia (of Grade 3); CSI-IV, cervical cancer stages I-IV; HPV, human papillomavirus;
HPV()/Cyt(), HPV negative and cytology negative; HPV(+)/Cyt(), HPV positive and cytology negative
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TABLE 2 S5 classifier sensitivity at the 0.80 cut-off in a cervical cancer referral group, stratified per histotype of cervical carcinoma, FIGO
stage, hrHPV status, sample type, age or country of origin
S5 sensitivity at cut-off 0.80
n/N Percentage 95% CI P valuec
Histotype of cervical carcinoma
Squamous cell carcinoma 509/510 99.80 99.10-99.95
Adenocarcinoma 29/29 100.0 97.34-100.0 .837
Adenosquamous cell carcinoma 1/1 100.0 12.8-100.0
Neuroendocrine carcinoma 4/4 100.0 26.86-100.0
FIGO stage
Stage I 244/245 99.60 99.25-99.83
Stage II 249/249 100.0 99.43-100.0 .687
Stage III 28/28 100.0 97.34-100.0
Stage IV 22/22 100.0 96.45-100.0
HPV statusd
HPV-positive 518/518 100.0 99.46-100.0
HPV16 379/379 100.0 99.36-100.0 .465a
HPV18 36/36 100.0 98.82-100.0 .587b
HPV31 20/20 100.0 96.45-100.0
HPV33 17/17 100.0 93.12-100.0
Other hr-HPV 66/66 100.0 98.93-100.0
HPV-negative 25/26 96.15 94.38-98.25
Sample type
Cervical scrape 383/384 99.73 98.34-99.96 .917
FFPE tissue 160/160 100.0 98.76-100.0
Age (years)
<25 7/7 100.0 64.87-100.0
25-29 38/38 100.0 98.62-100.0
30-39 133/133 100.0 99.32-100.0 .989
40-49 153/154 99.39 98.74-99.86
50-59 129/129 100.0 99.22-100.0
>60 83/83 100.0 99.02-100.0
Country of origin
Bhutan 50/50 100.0 98.89-100.0
Colombia 46/46 100.0 98.87-100.0
Ethiopia 70/70 100.0 98.98-100.0
Georgia 42/42 100.0 98.84-100.0 .892
India 50/50 100.0 98.89-100.0
Philippines 50/50 100.0 98.89-100.0
South Africa 49/49 100.0 98.88-100.0
Spain 50/50 100.0 98.89-100.0
United Kingdom 50/51 98.03 95.99-99.05
United States (New Mexico) 86/86 100.0 99.12-100.0
Total 543/544 99.81 98.34-99.96
Note: FIGO, Fédération Internationale de Gynécologie et d'Obstétrique; n = number of positive samples in a specified group; N = group total.
Abbreviations: CI, confidence interval; FFPE, formalin-fixed paraffin-embedded; HPV, human papillomavirus; hr-HPV, high-risk human papillomavirus.
aP value between HPV-positive and HPV-negative subgroups.
bP value among all subgroups in the HPV groups.
chrHPV genotype grouping performed by hierarchical genotype attribution, as detailed in materials and methods.
dDetermined by performing Fisher's exact test of independence.
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(Figure 2B). The most important decrease was observed in the
HPV()/Cyt() and HPV(+)/Cyt() groups. At a cut-off of 0.80, the
false positive rate in HPV()/Cyt() women was 26.32%
(95% CI = 23.90-29.94). This may be acceptable for a country desiring
very high sensitivity, where a strong healthcare system could accom-
modate the rather common false positives. The false positive rate
decreased to 0.92% (95% CI = 0.36-1.82) at both 2.62 and 3.70 cut-offs
(McNemar test χ2 ¼27:1, P< .0001) which would better suit countries
with lower screening capacity. However, the false positive rate of S5
in the HPV(+)/Cyt() was 52.74% (95% CI = 49.71-55.63) at 0.80
and showed a significant decrease trend to 27.22% (95% CI = 24.94-
29.53) at cut-off 2.62 and 18.26% (95% CI = 16.62-20.24) at cut-off
3.70 (Cuzick test for trend, P< .0001). These possible adjustments can
allow a customization of the S5 cut-off according to the country of
clinical implementation.
Although we observed a significant decrease in false positive rate
with the increase of the cut-off, a similar but less pronounced decrease
trend was observed in S5 positivity for CIN3 and cancer detection.
CIN3 sensitivity decreased from 87.26% (95% CI = 84.42-89.93) at
0.80 to 62.74% (95% CI = 60.13-65.25) at 3.70 (Cuzick test for trend,
P < .0001). Further, the S5 sensitivity for cancer decreased from
99.81% (95% CI = 98.34-99.96) at 0.80 to 95.77% (95% CI = 92.39-
97.40) at 3.70 (Cuzick test for trend, P= .005).
3.6 | Diagnostic potential of S5 classifier compared
to HPV16/18 testing
Table 3 presents the associations between HPV16/18 and S5 classi-
fier positivity at different cut-offs for the identification of CIN3+,
compared to the HPV(+)/Cyt(). HPV16/18 positivity was strongly
associated with CIN3+ development. The univariate OR of
HPV16/18 positivity for CIN3 was 2.86 (95% CI = 1.77-4.62), while
for cancer the OR was approximatively two times higher: 4.80
(95% CI = 3.13-7.96). The univariate ORs for all S5 cut-offs were
higher than the univariate ORs for HPV16/18 (P < .0001). Increased
ORs were observed for the bi-variable associations of HPV16/18 and
the S5 test regardless of the cut-off or the geographic location (all,
P < .0001). This indicates stronger associations between the combina-
tion of HPV16/18 positivity and S5 positivity and CIN3+ develop-
ment. Although the ORs for the bi-variable analysis of HPV16/18
positivity and S5 0.80 cut-off were significantly higher than the uni-
variate HPV16/18 ORs (P < .0001), the highest associations for CIN3
+ development were observed for S5 positivity at the 3.70 cut-off
(OR = 5.63, 95% CI = 3.26-9.73 for CIN3; and OR = 45.55,
95% CI = 24.67-73.38 for cervical cancer).
3.7 | S5-classifier performance in detecting
cervical cancers at the 3.70 cut-off
When the cut-off was increased to 3.70, the false positive rate in
HPV(+)/Cyt() was 9.54% (95% CI = 8.49-10.76), which was
approximatively 4-fold lower than at the 0.80 cut-off (39.54%,
95% CI = 37.20-41.86). The decrease in the false positive rate corre-
lates to an increase in specificity of the S5 classifier. Estimates of
specificity are presented in Table S3 for cervical cancer compared to
HPV()/Cyt() women or HPV(+)/Cyt() women (approximating a
currently relevant triage population). For both cases, increasing the cut-
off from 0.80 to 3.70 markedly improved specificity at a cost of sensi-
tivity (Table S3). In an HPV()/Cyt() population, specificity rose from
65.12% (95% CI= 54.59-74.35) at 0.80 to 100% (95.19-100.0) at 3.70.
TABLE 3 Univariate and bivariate
odds ratios (ORs) with 95% confidence
intervals (CIs) for the associations
between the different clinical outcomes
and HPV16/18 and/or S5 cut-offs in a
HPV(+)/Cyt() baseline
Variables OR 95% CI z value P valuea
CIN3 HPV16/18 2.86 1.77-4.62 4.30 Reference
S5 0.80 4.50 2.71-7.46 5.83 <.0001
S5 2.62 5.63 3.26-9.73 6.19 <.0001
S5 3.70 6.42 3.67-11.24 6.52 <.0001
HPV16/18 and S5 0.80b 3.26 2.01-5.30 4..79 <.0001
HPV16/18 and S5 2.62b 3.56 2.12-5.98 4.80 <.0001
HPV16/18 and S5 3.70b 5.01 2.82-8.90 5.49 <.0001
Cervical cancer HPV16/18 4.80 3.13-7.36 7.19 Reference
S5 0.80 20.94 7.89-51.71 7.22 <.0001
S5 2.62 36.21 20.9-62.73 12.80 <.0001
S5 3.70 45.55 24.67-73.38 13.49 <.0001
HPV16/18 and S5 0.80b 6.32 4.08-9.80 8.25 <.0001
HPV16/18 and S5 2.62b 9.87 6.11-15.96 9.35 <.0001
HPV16/18 and S5 3.70b 14.90 8.69-25.56 9.81 <.0001
Abbreviations: CIN, cervical intraepithelial neoplasia (of Grade 3); HPV, human papillomavirus.
aP value indicating an increased ORs compared to the reference HPV16/18. P value determined using
Fisher's test of independence.
bBivariate OR for the associations between HPV16/18 and S5 cut-offs (0.80, 2.62 and 3.70) and CIN3
and cervical cancer.
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TABLE 4 S5 classifier sensitivity at the 3.70 cut-off in a cervical cancer referral group, stratified per histotype of cervical cancer, FIGO stage,
hrHPV status, sample type, age or country of origin
S5 sensitivity at cut-off 3.70
n/N Percentage 95% CI P valuec
Histotype of cervical cancer
Squamous cell carcinoma 491/510 96.22 91.32-98.35
Adenocarcinoma 28/29 96.55 91.71-99.23
Adenosquamous cell carcinoma 1/1 100.0 91.81-100.0 .837
Neuroendocrine carcinoma 4/4 100.0 94.24-100.0
FIGO stage
Stage I 230/245 93.87 89.42-96.91
Stage II 242/249 97.18 93.62-99.00
Stage III 27/28 96.42 90.32-99.42 .687
Stage IV 22/22 100.0 97.76-100.0
HPV statusd
HPV-positive 510/518 98.45 92.72-99.46
HPV16 372/379 98.15 92.52-99.32
HPV18 34/36 94.44 91.60-98.72 .465a
HPV31 19/20 95.00 92.31-96.42 .587b
HPV33 16/17 94.11 90.22-95.41
Other hr-HPV 61/66 92.42 81.35-94.15
HPV-negative 19/26 73.07 56.85-86.82
Sample type
Cervical scrape 371/384 96.61 91.70-98.62
FFPE tissue 150/160 93.75 90.82-96.62 .917
Age (years)
<25 6/7 85.71 65.55-90.22
25-29 36/38 94.73 90.45-98.65
30-39 128/133 96.24 91.24-98.75
40-49 148/154 96.10 92.54-98.12 .989
50-59 122/129 94.57 89.79-96.12
>60 81/83 97.59 94.05-98.92
Country of origin
Bhutan 47/50 94.00 92.32-96.82
Colombia 40/46 86.95 78.35-92.92
Ethiopia 68/70 97.14 94.92-98.96
Georgia 40/42 95.23 92.98-97.35
India 48/50 96.00 94.12-97.59 .892
Philippines 48/50 96.00 94.12-97.59
South Africa 49/49 100.0 98.88-100.0
Spain 48/50 96.00 94.12-97.59
United Kingdom 48/51 94.11 93.72-96.59
United States (New Mexico) 84/86 97.67 94.72-98.68
Total 521/544 95.77 92.39-97.40
Note: FIGO, Fédération Internationale de Gynécologie et d'Obstétrique; n = number of positive samples in a specified group; N = group total.
Abbreviations: CI, confidence interval; FFPE, formalin-fixed paraffin-embedded; HPV, human papillomavirus; hr-HPV, high-risk human papillomavirus.
aP value among all subgroups in the HPV-positive group.
bP value between HPV-positive and HPV-negative subgroups.
chrHPV genotype grouping performed by hierarchical genotype attribution, as detailed in Section 2.
dDetermined by performing Fisher's exact test of independence.
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The same trend was observed in an approximated triage population.
Here, specificity increased from 50.60% (95% CI = 43.11-58.06) at
0.80 to 83.33% (95%CI= 76.97-88.21) at 3.70.
A total of 521 out of 544 women with any cancer type tested
positive for S5 at the 3.70 cut-off, yielding a sensitivity of 95.77%
(95% CI = 92.39-97.40). A lower proportion of the hrHPV-negative
cancer group tested S5 positive at a cut-off 3.70 compared to the
hrHPV-positive cancer group: 73.07% (95% CI = 56.85-86.82) vs
98.45% (95% CI = 92.72-99.46) (Fishers' test, P < .0001) as described
in Table 4. There were no other significant differences in S5 sensitivity
among histology, FIGO stage, hrHPV type, sample type, age and coun-
try of origin. These results indicate a highly consistent performance of
the S5 classifier in patients from different continents with respect to
detection of cancer.
3.8 | S5 classifier components proportion vary
with disease severity
On a component basis, individual EPB41L3 methylation was observed
to increase in a sigmoidal curve with disease progression. The Cuzick
test for trend was significant for HPV()/Cyt(), CIN3, CSI and CSII
(P < .0001). The second most important component of the S5 classi-
fier, HPV16 methylation, showed an increasing trend with disease
progression (Cuzick test for trend, both, P < .001) as well as a steep
increase from CIN3 to CSI-IV. Additionally, both HPV18 and HPV33
methylation showed a linear increase with disease progression (Cuzick
test for trend, both, P < .01) as described in Figure S3.
The weight of each component of the S5-classifier was plotted
for HPV(+)Cyt(), CIN3 and the cancer CSI-IV groups in Figure 3. The
Cuzick test for trend showed an increasing trend of EPB41L3 weight
with disease lesion, z = 8.21 (P < .0001). EPB41L3 weight plateaus at
CSII. Unconditional logistic regression models showed the strength of
the association between EPB41L3 methylation, severity of lesion and
age. The relationship between EPB41L3 methylation was stronger for
severity of lesion: F = 367.50, P < .0001 than age (F = 81.0,
P < .0001). This indicates that host EPB41L3 methylation might have a
good potential to predict disease progression, independent of increas-
ing natural epigenetic methylation levels occurring with age.
Interestingly, the relative proportion of the HPV components of
the S5-classifier decreased slightly with severity of lesion (Cuzick test
for trend, z = 6.52, P < .0001). HPV16 had the highest weight out of
all viral components; however, this was 1.8 times lower than the
weight of EPB41L3 in CSII+ specimens.
4 | DISCUSSION
To our knowledge, our study represents one of the most comprehen-
sive assessments of viral and host cell DNAmethylation data in invasive
cervical cancer to date, particularly given its multi-site dimension(s) and
number of cases of high grade and invasive disease.27 We show that
there is a strong increasing trend of S5 DNA methylation score with
cervical disease severity in our global collection of samples. Our results
also show a very high S5 sensitivity for CIN3+ at the predefined cut-off
of 0.80, while there was high to moderate sensitivity at the exploratory
cut-offs of 2.62 and 3.70, respectively.
We found an S5 test sensitivity of 91.18% (186/204) for CIN3 and
99.81% (543/544) for cervical cancer detection at the predefined cut-off
of 0.80.9 At this cut-off, S5 sensitivity for cervical cancer was higher than
the sensitivity of HPV DNA testing: 95.21% (518/544) (McNemar test
χ2 ¼5:08, P = .032). Additionally, at the S5 cut-off of 3.70, previously
demonstrated useful in LMIC settings,12 we found a sensitivity of
62.74% (128/204) for CIN3 and 95.77% (521/544) for cervical
cancer.
This study complements previous results in Colombia,10 Canada11
and Mexico,12 by including data on cancers from additional countries and
thus describing a larger study for cervical cancer identification. A recent
Dutch study of 519 cervical cancer samples, FAM19A4/miR124-2 methyl-
ation analysis yielded a sensitivity of 98.30% (510/519).27 Additionally, the
four-gene methylation marker panel comprising of the host genes JAM3,
EPB41L3, TERT and C13ORF18 identified 94.20% (65/69) of cervical can-
cers.28 S5 demonstrated a slightly higher sensitivity of 99.81% (543/544)
compared to the above-mentioned tests (P = .047 and P = .029, respec-
tively). Most importantly, S5 detected 25 out of 26 hrHPV-negative can-
cers, which were not explored in other studies.
We explored the performance of the S5 classifier at three cut-








































F IGURE 3 S5 component breakdown in HPV+ NEG, CIN3 and
CSI-IV samples. The weight of the methylation on the S5
components: EPB41L3, HPV16, HPV18, HPV31 and HPV33 has been
calculated for each group. Percentages of EPB41L3 and HPV16
weights in the classifier are noted at the top of the corresponding
bars. HPV methylation becomes less important vs EPB41L3 as the
lesions become more advanced; however, EPB41L3 weight in the
classifier does not change after Stage II cancer. CIN, cervical
intraepithelial neoplasia (of Grade 3); CSI-IV, cervical cancer stages
I-IV; HPV, human papillomavirus
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women tested positive for S5, which indicates either a potential speci-
ficity issue of the tool in our selected group of HPV()Cyt() women
or a higher than expected prevalence of occult CIN in these women.
The lowest false positive rate was observed at the 3.70 cut-off
(0.92%), a cut-off at which 95.77% (521/544) of cancer cases were
still identified. A similar trend was observed with CIN3 cases
(Table S2). Due to the referral nature of the samples included, exact
specificity values could not be calculated; however, estimated values
are provided in Table S3.
Our data on S5 sensitivity combined with our earlier results from
studies in the United Kingdom, Canada, Mexico and Colombia suggest
that the prevalence of HPV infection as well as the difference in
screening capacity and performance of populations can affect disease
prevalence, thereby arguably the optimal cut-off of S5 could be made
‘setting specific’.9-12 An increased cut-off with a lower number of
false positives rate would maximise the detection of cancer, which is
favourable in countries with minimal screening resources such as in
LMICs. Indeed, in settings with no or patchy screening programmes,
an increased cut-off might be justified.11,12,29
The major strengths of our study are its size, the incorporation of
sample set that reflects diverse settings from 10 different countries
spanning five continents. Our study highlights the general trend of
increasing DNA methylation with disease progression.
Although HPV infection is an important co-factor in cervical can-
cer development, a small proportion of cervical cancer samples in the
study tested hr-HPV negative as confirmed by HPV testing with mul-
tiple assays. Though rare, these cases represent a challenge for detec-
tion in the current primary hr-HPV screening programme. Our data
show that nearly all of these cancers (25/26) were identified by the
S5 classifier at a cut-off of 0.80. Regardless of the cut-off examined,
performance of the S5 classifier was uniform among the stratified
groups: histology, FIGO stage, hrHPV status, hrHPV type, sample
type, age and country of origin.
A limitation to our study is that all CIN3 and cervical cancer cases
come from referral populations and do not accurately represent those
that may be apparent in the screening population or those that do not
present to clinics. The proportion of rare histological subtypes in our
study was also small, so this element would benefit from further
investigation. Moreover, much more emphasis was placed on cancers
FIGO stage I and II as previously published data indicate that aberrant
methylation is an early event in cervical carcinogenesis.14,29 An inten-
tional limitation of our study is that we excluded CIN1 and CIN2
which would be present in a real-world setting. Addition of these sam-
ples to our study in realistic proportions would likely lower the sensi-
tivity and specificity of the S5 test. There is a further limitation in our
selection of the cytology negative women who were presumed to
have no disease on the basis of cytological testing. Although we
divided these women into HPV+ and HPV groups, these women
may not be representative of the routine screening populations in
many geographic locations including in Europe and the United States.
Therefore, the aim of our present work was to assess a larger panel of
CIN3+ samples to confirm the sensitivity and robustness of the assay
for the detection of significant disease.
The present findings highlight the major contribution of host
EPB41L3 methylation in the S5 score. We showed that the relation-
ship between EPB41L3 methylation was approximatively 4.5 times
stronger for severity of lesion than age (P < .0001). This indicates that
host EPB41L3 methylation might have a strong potential to predict
disease progression, independent of increasing natural epigenetic
methylation levels occurring with age. This is in line with previously
published data on the S5 where it better identified women with CIN2
that were more likely to progress to higher stages of the disease.8
Additionally, the weight of EPB41L3 methylation shows an increasing
trend (P < .0001, Cuzick test for trend), up to cervical cancer FIGO
stage II, where it plateaus. However, the strength of this observation
is limited by the decreased number of cervical cancer samples of FIGO
stage III and IV, included in the study.
The COVID-19 pandemic points towards a shift to self-sampling
for hrHPV primary screening to reduce the burdens on the healthcare
professionals and access women who do not respond to screening
invitations. Having the possibility to triage hrHPV-positive women
from the same self-collected specimen would bring many advantages
including a reduction in logistical issues associated to systematic
screening as well as reducing the subjectivity of cytology.30-34 A pilot
study tested the accuracy of S5 classifier in cervical self-samples. S5
showed a statistically significant separation between <CIN2 and CIN2
+ samples for both urine and cervical self-samples (P ≤ .0001). At the
pre-defined cut-off of 0.80, the sensitivity for cervical self-samples
was 71% and specificity 68% and for urine samples was 66% and
specificity 72%.33
In conclusion, our study shows that the S5 classifier at a cut-off
of 0.80 identifies more than 90% CIN3 cases and almost 100% of
cervical cancers, independent of histology, FIGO stage hrHPV status,
hrHPV genotype, sample type and geographical origin. Adjustment
of the cut-off leads to an increase in specificity with only a small
decrease in sensitivity. The 3.70 cut-off could allow for a better tri-
age modality for LIMC where screening is not performed as system-
atically as in higher income countries. Additionally, high methylation
levels on the host gene component of the S5 classifier, EPB41L3 is
associated with higher severity of the disease, indicating prognostic
potential. Thus, considering the growing acceptability of self-sam-
pling, our results support the utility of the S5 classifier as a credible
tool for enhanced risk stratification of women in cancer screening
programmes.
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